KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Molina Healthcare (MOH) Other Accumulated Expenses (2016 - 2025)

Molina Healthcare's Other Accumulated Expenses history spans 16 years, with the latest figure at $4.8 billion for Q3 2025.

  • For Q3 2025, Other Accumulated Expenses rose 2.37% year-over-year to $4.8 billion; the TTM value through Sep 2025 reached $4.8 billion, up 2.37%, while the annual FY2024 figure was $4.6 billion, 10.37% up from the prior year.
  • Other Accumulated Expenses for Q3 2025 was $4.8 billion at Molina Healthcare, down from $4.9 billion in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $4.9 billion in Q2 2025 and bottomed at $2.8 billion in Q1 2021.
  • The 5-year median for Other Accumulated Expenses is $3.8 billion (2023), against an average of $4.0 billion.
  • The largest annual shift saw Other Accumulated Expenses skyrocketed 50.1% in 2021 before it fell 2.6% in 2023.
  • A 5-year view of Other Accumulated Expenses shows it stood at $3.4 billion in 2021, then grew by 4.91% to $3.5 billion in 2022, then rose by 19.16% to $4.2 billion in 2023, then rose by 10.37% to $4.6 billion in 2024, then increased by 4.4% to $4.8 billion in 2025.
  • Per Business Quant, the three most recent readings for MOH's Other Accumulated Expenses are $4.8 billion (Q3 2025), $4.9 billion (Q2 2025), and $4.8 billion (Q1 2025).